Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Anavex Lf SC
(NQ:
AVXL
)
5.595
-0.005 (-0.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Anavex Lf SC
< Previous
1
2
3
4
5
6
7
8
Next >
Is Anavex Life Sciences Stock a Buy Now?
February 23, 2023
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
Via
The Motley Fool
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
February 09, 2023
Short-sellers have piled into this clinical-stage biopharma stock.
Via
The Motley Fool
Why Anavex Life Sciences Stock Bolted Higher in January
February 08, 2023
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results.
Via
The Motley Fool
Anavex Life Sciences Stock Shows Improved Price Strength Rating
February 07, 2023
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75.
Via
Investor's Business Daily
Earnings Preview: Anavex Life Sciences
February 06, 2023
Via
Benzinga
3 Biotech Stocks Under $15 Worth a Second Look in 2023
January 18, 2023
All three stocks have promising therapies that could drive revenue in the coming years.
Via
The Motley Fool
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
January 10, 2023
Via
Benzinga
Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today
December 27, 2022
Via
Benzinga
Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years
December 08, 2022
Via
Benzinga
Anavex Catapults On Alzheimer's Results — But Math Question Clouds The Data
December 02, 2022
A math error could have clouded the drug's actual benefits.
Via
Investor's Business Daily
Top Picks For 2023: Anavex Life Sciences
January 06, 2023
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett...
Via
Talk Markets
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
January 03, 2023
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market...
Via
Benzinga
Analyzing Anavex Life Sciences's Short Interest
December 21, 2022
Anavex Life Sciences's (NASDAQ:AVXL) short percent of float has risen 17.06% since its last report. The company recently reported that it has 11.91 million shares sold short, which is 15.71% of all...
Via
Benzinga
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
December 17, 2022
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
Via
The Motley Fool
Is Anavex Life Sciences a Buy?
December 13, 2022
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Via
The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,500 Today
December 02, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
December 06, 2022
Via
Benzinga
Is Anavex Life Sciences a Smart Stock to Buy Now?
December 03, 2022
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it?
Via
The Motley Fool
Dow Drops 100 Points; Asana Shares Plummet
December 02, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 100 points on Friday.
Via
Benzinga
Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday's Mid-Day Session
December 02, 2022
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) rose 42% to $0.54 after dipping 56% on Thursday.
Via
Benzinga
Anavex Life Sciences (NASDAQ: AVXL) Says Phase 2b/3 for ANAVEX2-73 Met Primary and Secondary Endpoints Reducing Cognative Decline in Patients with Early Alzheimer’s
December 02, 2022
Anavex Life Sciences Corp. (NASDAQ: AVXL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and
Via
Spotlight Growth
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
December 02, 2022
Via
Benzinga
Gold Down 1%; Samsara Shares Spike Higher
December 02, 2022
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 75 points on Friday.
Via
Benzinga
Why Anavex Life Sciences Stock Is Surging Today
December 02, 2022
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate.
Via
The Motley Fool
Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News
December 02, 2022
Rigel Pharmaceuticals (RIGL) stock is heading higher on Friday after getting approval from the FDA for its leukemia treatment.
Via
InvestorPlace
Why Is Anavex Life Sciences (AVXL) Stock Up 30% Today?
December 02, 2022
Anavex Life Sciences (AVXL) stock is rocketing higher on Friday following positive results from an Alzheimer’s clinical trial.
Via
InvestorPlace
Smartsheet, Samsara, Anavex Life Sciences And Some Other Big Stocks Moving Higher On Friday
December 02, 2022
U.S. stocks traded mostly lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Dow Tumbles 300 Points After US Economy Adds 263,000 Jobs
December 02, 2022
U.S. stocks traded lower this morning, with the Dow Jones falling more than 300 points on Friday following the release of jobs data for November.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 02, 2022
Via
Benzinga
Jim Cramer Says This Stock Is Dynamite: 'I Do Not Want You To Do A Thing Other Than Ride It'
December 01, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Williams Companies, Inc. (NYSE: WMB) is "terrific." He recommended buying the stock.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.